Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E7777 Prior to CAR-T Therapy for Relapsed/Refractory Large B-Cell Lymphomas
NCT04855253Phase 2Suspended
- Sponsor
- Masonic Cancer Center
- Start
- Jun 2021
- Primary completion
- Sep 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of denileukin diftitox in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), follicular lymphoma (FL), sponsored by Masonic Cancer Center. Started Jun 2021; status: suspended.
02
Drugs
denileukin diftitox
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04855253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04855253.